Analyse ResMed Inc. (RMD) — Kairos Score 65/100

À propos de ResMed Inc.

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Informations clés

🕴️ Activité des initiés (90 jours)

9 transactions — 0 achats et 3 ventes déclarés par les dirigeants de ResMed Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur RMD dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RMD.

• ResMed’s Quarterly Earnings Preview: What You Need to Know
• mHealth Solutions Market Forecasts Growth from $109.05B (2026) to $275.44B by 2031, Profiling Philips, Medtronic, Abbott, Dexcom, ResMed & 20 Other Key Players

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.